US-based Cordis has launched its Saber PTA dilatation catheter to treat patients with peripheral arterial disease (PAD).
Currently, the Saber Catheter is cleared for use and is available in Europe, the US and Japan in balloon diameters of 2mm-10mm and lengths of 20mm-300mm.
The company said that its new product provides outstanding crossability and a comprehensive offering of balloon sizes on the widely-used .018in over-the-wire platform.
The Saber PTA dilatation catheter enables physicians to treat a wider range of PAD patients with a single balloon brand.
It has been designed to dilate stenoses in iliac, femoral, ilio-femoral, popliteal, infrapopliteal and renal arteries, as well as to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae.
Saber catheter is also indicated for post-dilation of balloon-expandable and self-expanding stents in the peripheral vasculature.
The new device combines a durable dual layer hydrophilic coating with a low-profile body and new moulded tip design to enhance crossability.
According to the company, the device has high-rated burst pressures of up to 18atm due to its construction with trusted DURALYN Material.
Cordis worldwide president Celine Martin said: "With the addition of both the Chocolate Balloon Catheter and extensive line of Saber catheter products, we’ve strengthened and deepened our overall offering in both the specialty and workhorse PTA segments."
Approximately 27 million people in Western Europe and North America are expected to have PAD, which is associated with significant morbidity and mortality.
Image: Cordis’s Saber PTA dilatation catheter. Image: courtesy of Business Wire/Cordis Corporation.